Neogen Chemicals reports Q2 FY26 results with PAT down 69% consolidated; continues strategic battery materials expansion
Neogen Chemicals announced Q2 FY26 results: consolidated revenue up 8%, but PAT significantly down 69% due to costs and startup losses. Strategic battery materials expansion continues.
The impact is medium. The significant decline in PAT is a short-term negative, but the company's proactive steps in raising debt for rebuilding the Dahej plant, strategic appointments, and ongoing expansion in the high-growth battery materials segment indicate a focus on long-term value creation and recovery.
The sentiment is negative primarily due to a significant 69% decline in consolidated Profit After Tax (PAT) and a 37% decline in standalone PAT for Q2 FY26. This was driven by increased operational costs, higher insurance premiums, and substantial finance costs, compounded by the Neogen Ionics business being in startup mode and the Dahej plant fire incident.
* Neogen Chemicals Limited has announced its un-audited financial results for the quarter and half year ended September 30, 2025. * Consolidated Financial Highlights for Q2 FY26: * Revenue increased by 8% to ₹208.7 crore compared to ₹193.4 crore in Q2 FY25. * EBITDA decreased by 13% to ₹30.0 crore from ₹34.5 crore in Q2 FY25, with margins at 14.4%. * Profit After Tax (PAT) significantly decreased by 69% to ₹3.4 crore from ₹11.0 crore in Q2 FY25, with margins at 1.6%. The consolidated performance was impacted by Neogen Ionics being in a startup mode. * Standalone Financial Highlights for Q2 FY26: * Revenue grew by 7% to ₹206.7 crore compared to ₹193.1 crore in Q2 FY25. * EBITDA decreased by 4% to ₹35.0 crore from ₹36.5 crore in Q2 FY25, with margins at 16.9%. * PAT decreased by 37% to ₹9.3 crore from ₹14.9 crore in Q2 FY25, with margins at 4.5%. * EBITDA and PAT were constrained by higher employee costs, increased insurance premiums post-fire, job work/conversion costs, higher finance costs for inventory and plant rebuild, and lower utilization of the Dahej plant. Some costs covered by Loss on Profit Policy will be claimed in FY27. * Key Updates and Expansion Initiatives: * The Board approved the separation of Chairman and Managing Director roles, effective October 1, 2025. Mr. Anurag Surana was appointed Non-Executive Chairman of Neogen Chemicals, and Mr. Sanjay Mehta as Non-Executive Chairman of Neogen Ionics. Mr. TCN Sai Krishnan was appointed Executive Director of Neogen Chemicals. * The company successfully raised ₹200 crore through private placement of Non-Convertible Debentures (NCDs) to fund growth projects and expedite the rebuilding of the Organic Chemicals plant in Dahej SEZ. * Neogen Ionics (Battery Chemicals Business): * 200 MTPA capacity for Lithium Electrolyte Salts commissioned, with trial production ongoing for the remaining 200 MTPA. * 2,000 MT Electrolyte plant fully commissioned in FY25; an additional 1,100 MT is expected by December 2025, and 1,000 MT by Q1 FY27. * Commercial production for Electrolyte from the Greenfield facility at Pakhajan, Dahej PCPIR, is expected in H1 FY27, and Lithium Electrolyte Salt in H2 FY27. * An Indian Giga scale customer completed the Production Part Approval Process (PPAP) and approved Neogen Ionics’ Dahej plant for long-term commercial supply of Electrolyte. * A Joint Venture Agreement was executed with Morita Investment (MIL) to form Neogen Morita New Materials Limited (NML) for producing solid LiPF6 salt, with NIL holding a minimum of 80% and MIL a maximum of 20%. * Management Commentary by Dr. Harin Kanani, MD: Highlighted operational resilience, strategic focus on high-growth battery materials, swift Dahej organic plant recovery, anticipated ramp-up next year, and commitment to corporate governance and long-term value creation.
What to do with a filing like this
Neogen Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Neogen Chemicals Limited. Read the original for the full detail.